unknown
Stage
1
Investors
About
iFAST develops a rapid antimicrobial susceptibility testing (AST) diagnostic that reduces time-to-result from over 48 hours to approximately 3 hours, aiming to address antimicrobial resistance.
Explore iFAST's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.